AvalonBay Communities vs AbbVie

About

AvalonBay Communities, Inc. is an Arlington, Virginia-based apartment REIT — publicly traded on the New York Stock Exchange (NYSE: AVB) as an S&P 500 Real Estate component — developing, redeveloping, acquiring, and managing high-quality apartment communities primarily in major coastal metropolitan markets including New England (Boston, metro Boston), Mid-Atlantic (Washington DC, Virginia), Pacific Northwest (Seattle), Northern and Southern California (San Francisco Bay Area, Los Angeles, San Diego), and the Southeast expansion markets (Atlanta, Dallas, Denver, Raleigh-Durham) through approximately 3,000 employees. AvalonBay owns or holds direct or indirect interests in 301 apartment communities with 90,000+ apartment homes, with the portfolio concentrated in knowledge economy metros with above-average median household income demographics and technology company employment concentration. In fiscal year 2024, AvalonBay reported revenues of approximately $2.96 billion and same-store NOI growth of approximately 2.6% — moderating from the exceptional 2021-2022 post-COVID rent surge as new apartment supply (particularly in Southeast expansion markets) created competitive conditions. CEO Benjamin Schall leads AvalonBay's capital allocation strategy of maintaining a diversified coastal portfolio while selectively expanding into high-growth Southeast and Mountain West markets (AVB Expanded markets strategy — Dallas, Denver, Atlanta, Southeast — targeting 25% of NOI from these markets by 2027 versus 10% historically) to balance coastal market premium valuations and rent growth cyclicality. AvalonBay's development pipeline (30+ communities under construction or development representing 10,000+ future apartment homes) maintains a perpetual development engine that creates below-market-value apartment communities through new construction when completed properties stabilize at market rents.